#USA #San Diego #Olverembatinib #Ascentage Pharma #Lisaftoclax

Promising Results for Pediatric Leukemia Treatment at ASH 2024

In the latest news from the 66th American Society of Hematology (ASH) Annual Meeting, Ascentage Pharma presented groundbreaking findings regarding a combination treatment for pediatric patients suffering from relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (R/R Ph+ ALL).

This innovative combination involves olverembatinib (HQP1351), the first approved third-generation BCR-ABL inhibitor in China, used alongside the investigational Bcl-2 inhibitor, lisaftoclax (APG-2575). The study showcased significant clinical benefits, offering a new therapeutic strategy that does not include traditional chemotherapy or immunotherapy.

Key Findings

The data released at ASH 2024 revealed results that are particularly compelling. Specifically, the combination therapy boasted an impressive complete response (CR) rate of 83.3%, alongside a measurable residual disease (MRD) negativity rate of 71.4%. These outcomes were observed in a cohort of children and adolescents between the ages of 11 and 15 who had previously faced treatment challenges with other therapies.

The study involved a total of ten patients with relapsed or refractory Ph+ ALL, all of whom had a history of resistance to tyrosine kinase inhibitors (TKIs). Administered as a two-stage regimen, olverembatinib was given prior to being combined with varying doses of lisaftoclax, showcasing the potential for a safe, effective treatment pathway without the harsh side effects associated with standard chemotherapy.

The Study's Presentation

The data, which received the Abstract Achievement Award at the conference, was a focal point in the hematology community's discussions on advancements in treating pediatric leukemia. Prof. Xiaofan Zhu from the Institute of Hematology noted,